Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{191299,
        author = {PRADEEP B MIRJE and RAVI SONDUR and BASAVARAJ SHIDAGONNAVAR},
        title = {DEVELOPMENT AND CHARACTERIZATION OF RIVASTIGMINE-LOADED TRANSFEROSOMAL VESICLES FOR ENHANCED TRANSDERMAL DELIVERY},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {6976-6987},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=191299},
        abstract = {The present study was aimed at the development and characterisation of rivastigmine-loaded Transferosomal vesicles for enhanced transdermal drug delivery. Transferosomes were formulated using soya lecithin, cholesterol, and different edge activators (Tween 80 and Span 80) by the thin film hydration technique. The prepared formulations (F1–F8) were evaluated for compatibility, vesicle morphology, particle size, zeta potential, percentage yield, drug entrapment efficiency, in vitro drug release, release kinetics, and stability. FTIR studies confirmed the compatibility of rivastigmine with formulation excipients, indicating the absence of chemical interactions. Particle size analysis revealed nano-sized vesicles ranging from 175 to 189 nm with acceptable zeta potential values (–22 to –28 mV), ensuring formulation stability. SEM analysis showed spherical vesicles with smooth surfaces and uniform morphology. Among all formulations, F6 exhibited the highest yield (85.96%) and drug entrapment efficiency (88.15%). In vitro drug release studies demonstrated sustained release of rivastigmine up to 12 hours, with the optimised formulation F6 showing maximum cumulative drug release (98.80%). Kinetic analysis indicated that the drug release followed first-order kinetics and the Higuchi diffusion model. Stability studies conducted as per ICH guidelines showed no significant changes in drug release and physical characteristics over three months. Overall, the results suggest that transferosomal vesicles are a promising carrier system for the transdermal delivery of rivastigmine, offering sustained release and improved therapeutic potential.},
        keywords = {Rivastigmine, FTIR Studies, Thin film hydration method, Transferosomes, In vitro drug release studies},
        month = {January},
        }